Coronavirus disease 2019 (COVID-19): Hypercoagulability
Coronavirus disease
2019 (COVID-19): Hypercoagulability
Hypercoagulable state: In COVID-19 disease a hypercoagulable
state can be observed that usually associates
acute inflammatory alteration & lab findings that’re different from that of
acute disseminated intravascular coagulation (DIC),
save for those with very severe disease. Fibrinogen &
D-dimer
levels are usually elevated, with typically only modest
prolongation of PT & aPTT & mild thrombocytosis or thrombocytopenia.
The finding of a lupus anticoagulant (LA) is
common in subjects with a prolonged aPTT. Pathogenesis of these alterations is
not completely understood, and there may be many contributing
agents related to the acute inflammatory response to COVID-19.
Risk of Thrombosis: The incidence of venous thromboembolism
(VTE) is markedly elevated, particularly
in ICU ptns, with case series findings
of prevalence of about 25-43 % in ICU ptns, in
the presence of prophylactic-dose anti-coagulation.
Pulmonary microvascular
thrombosis is also prevalent. In addition, the risk of arterial thrombotic events e.g. stroke,
MI, and ischemic
limbs have been also prevalent.
Lab testing: All ptns hospitalized with COVID-19 should
have a basal profile of CBC with platelet count, PT,
aPTT, fibrinogen,
& D-dimer. Repeating these
profile is performed according to ptn's clinical
situation. OPD ptns do not require coagulation
tests. The main target of profile is to provide prognostic interpretation that
may be reflected on the level of ptn’s care.
Imaging: Imaging tests are appropriately indicated for a
suspected cases of VTE if available. If the standard
diagnostic examinations are not available,
other therapeutic options (e.g. compression
ultrasonography) may be applied. Atypical lab alterations for COVID-19 should
be further assessed.
Management: Management is challenging due to the acuity of
the illness and a paucity of high-quality evidence regarding efficacy and
safety of different approaches to prevent or ttt thromboembolic
complications of the disease. The
following:
1)
Thromboprophylaxis: All hospitalized
ptns should commence the thrombo-prophylaxis therapy unless there is contraindication.
LMW is of choice, but unfractionated heparin
may be used if LMW heparin is not available or if renal function is
highly compromised. Some institutional regimens involve more aggressive form of anticoagulation with intermediate
or even therapeutic-doses of anticoagulation
for thrombo-prophylaxis. Ptns with no
VTE are
not currently provided thrombo-prophylaxis after discharge. An appropriate period of thrombo-prophylaxis
after hospital discharge may be advised in selected cases.
2)
VTE ttt: Therapeutic-dosage (full-dose) of anticoagulation therapy is warranted to ttt DVT & pulmonary embolism (PE), unless there’s clear contraindication. This regimen should be continued
for minimum 3 mo.
3)
Bleeding: Bleeding
is less commonly observed than thrombosis but can be seen. If occurs, ttt is the same as in
non-COVID-19
ptns that include [blood/plasma
transfusion, anticoagulant reversing techniques, or particular products specified
for an underlying bleeding disorder].
4)
Areas of uncertainty: Participation in clinical trials is
encouraged in order to improve understanding of the most
effective and safest means of
preventing and ttt thrombotic sequelae of COVID-19.
Investigational disease-specific therapy may affect the thrombotic incidence, but the impact
of these therapies on hemostasis in this cohort still uncertain.
REFERENCES
2.
Lowenstein CJ,
Solomon SD. Severe COVID-19 Is a Microvascular Disease. Circulation 2020;
142:1609.
3.
Libby P, Lüscher
T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41:3038.
5.
Hidalgo A. A
NET-thrombosis axis in COVID-19. Blood 2020; 136:1118.
COMMENTS